Hematology NewsAn off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019B Cell LymphomaCellular TherapyLymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Hematology NewsOff-the-shelf cellular therapy shows promise in the labDecember 8, 2019B Cell LymphomaCLLCellular TherapyImmuno-oncologyImmunotherapy
Hematology NewsBispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaCellular TherapyImmuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
Hematology NewsHigh complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaCellular TherapyImmuno-oncologyImmunotherapyLymphoma & Plasma Cell DisordersRare Diseases
Hematology NewsASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Cellular TherapyALLMultiple MyelomaLymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Oncology PracticeCombo elicits lasting responses in metastatic melanomaNovember 25, 2019MelanomaImmunotherapyImmuno-oncology
Hematology NewsWill TP53-mutated AML respond to immunotherapy?November 18, 2019AMLLeukemia, Myelodysplasia, TransplantationImmunotherapyCellular TherapyTranslational ResearchRare Diseases
Hematology NewsCAR T-cell ‘cocktail’ may overcome antigen escape relapseNovember 18, 2019B Cell LymphomaImmunotherapyLymphoma & Plasma Cell DisordersALLCellular Therapy
Oncology PracticeDon’t miss neuromuscular complications of cancer immunotherapyNovember 14, 2019Immunotherapy
Oncology PracticeNeoantigen vaccine appears safe and active in NSCLCNovember 14, 2019Lung CancerImmunotherapyImmuno-oncology
Oncology PracticeCombo produces disappointing PFS, promising OS in metastatic colorectal cancerNovember 13, 2019GastroenterologyImmunotherapyImmuno-oncologyGastrointestinal Cancer
Hematology NewsArmored CAR T cells elicit responses in NHL patientsNovember 12, 2019B Cell LymphomaDLBCLLymphoma & Plasma Cell DisordersFollicular LymphomaImmunotherapyCellular TherapyImmuno-oncology
Oncology PracticeCombo shows promise for checkpoint inhibitor-refractory urothelial carcinomaNovember 12, 2019Genitourinary CancerImmunotherapyImmuno-oncology
Oncology PracticeTLR9 agonist may overcome resistance to anti–PD-1 therapy in melanomaNovember 12, 2019MelanomaImmunotherapyImmuno-oncology
Oncology PracticeMolecule exhibits activity in heavily pretreated, HER2-positive solid tumorsNovember 11, 2019Breast CancerGynecologic CancerGastroenterologyImmunotherapyImmuno-oncologyGastrointestinal Cancer
